These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 24667461)

  • 1. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes.
    Ceriello A; Novials A; Canivell S; La Sala L; Pujadas G; Esposito K; Testa R; Bucciarelli L; Rondinelli M; Genovese S
    Diabetes Care; 2014 Jul; 37(7):1938-43. PubMed ID: 24667461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes.
    Ceriello A; Novials A; Ortega E; Canivell S; Pujadas G; La Sala L; Bucciarelli L; Rondinelli M; Genovese S
    Cardiovasc Diabetol; 2013 Jun; 12():97. PubMed ID: 23806096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin C further improves the protective effect of glucagon-like peptide-1 on acute hypoglycemia-induced oxidative stress, inflammation, and endothelial dysfunction in type 1 diabetes.
    Ceriello A; Novials A; Ortega E; Canivell S; La Sala L; Pujadas G; Bucciarelli L; Rondinelli M; Genovese S
    Diabetes Care; 2013 Dec; 36(12):4104-8. PubMed ID: 24130351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: a preliminary report.
    Ceriello A; Esposito K; La Sala L; Pujadas G; De Nigris V; Testa R; Bucciarelli L; Rondinelli M; Genovese S
    Cardiovasc Diabetol; 2014 Nov; 13():140. PubMed ID: 25407792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The simultaneous control of hyperglycemia and GLP-1 infusion normalize endothelial function in type 1 diabetes.
    Ceriello A; De Nigris V; Pujadas G; La Sala L; Bonfigli AR; Testa R; Uccellatore A; Genovese S
    Diabetes Res Clin Pract; 2016 Apr; 114():64-8. PubMed ID: 27103371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes.
    Ceriello A; Esposito K; Testa R; Bonfigli AR; Marra M; Giugliano D
    Diabetes Care; 2011 Mar; 34(3):697-702. PubMed ID: 21273492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes.
    Ceriello A; Novials A; Ortega E; Canivell S; La Sala L; Pujadas G; Esposito K; Giugliano D; Genovese S
    Diabetes Care; 2013 Aug; 36(8):2346-50. PubMed ID: 23564922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a continuous GLP-1 infusion compared with a structured insulin infusion protocol to reach normoglycemia in nonfasted type 2 diabetic patients: a clinical pilot trial.
    Sourij H; Schmölzer I; Kettler-Schmut E; Eder M; Pressl H; Decampo A; Wascher TC
    Diabetes Care; 2009 Sep; 32(9):1669-71. PubMed ID: 19528368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving drug-like properties of insulin and GLP-1 via molecule design and formulation and improving diabetes management with device & drug delivery.
    Pechenov S; Bhattacharjee H; Yin D; Mittal S; Subramony JA
    Adv Drug Deliv Rev; 2017 Mar; 112():106-122. PubMed ID: 28153578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state.
    Egan JM; Meneilly GS; Habener JF; Elahi D
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3768-73. PubMed ID: 12161508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
    Trujillo JM; Nuffer W
    Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
    Hare KJ
    Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus.
    McCormick LM; Heck PM; Ring LS; Kydd AC; Clarke SJ; Hoole SP; Dutka DP
    Cardiovasc Diabetol; 2015 Aug; 14():102. PubMed ID: 26253538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute peripheral administration of synthetic human GLP-1 (7-36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: a potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?
    Daousi C; Pinkney JH; Cleator J; Wilding JP; Ranganath LR
    Regul Pept; 2013 May; 183():54-61. PubMed ID: 23499806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans.
    Stegenga ME; van der Crabben SN; Levi M; de Vos AF; Tanck MW; Sauerwein HP; van der Poll T
    Diabetes; 2006 Jun; 55(6):1807-12. PubMed ID: 16731846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperglycemia potentiates the slowing of gastric emptying induced by exogenous GLP-1.
    Plummer MP; Jones KL; Cousins CE; Trahair LG; Meier JJ; Chapman MJ; Horowitz M; Deane AM
    Diabetes Care; 2015 Jun; 38(6):1123-9. PubMed ID: 25784665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of insulin on fasting and meal-stimulated somatostatin-like immunoreactivity in noninsulin-dependent diabetes mellitus: evidence for more than one mechanism of action.
    Gutniak M; Grill V; Efendić S
    J Clin Endocrinol Metab; 1986 Jan; 62(1):77-83. PubMed ID: 2866196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin therapy has a complex relationship with measure of oxidative stress in type 2 diabetes: a case for further study.
    Monnier L; Colette C; Michel F; Cristol JP; Owens DR
    Diabetes Metab Res Rev; 2011 May; 27(4):348-53. PubMed ID: 21309055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.